Injection Pen Market 2019 Market Challenge, Driver, Trends & Forecast to 2023

 

Market Highlights

The injection pen is a standard delivery device for accurate subcutaneous delivery. A number of factors such as increasing prevalence of chronic diseases, ongoing technological advancements, and improving regulatory framework are fueling the growth of the global injection pen market. According to International Diabetes Federation, in 2016, it was estimated that 420 million adult population were suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6146 

Moreover, technological advancements in injection pens and increasing product launch by prominent players are likely to drive the market growth during the forecast period. For instance, in 2017, Sanofi launched AllStar pro reusable pen injector across the European market.  Furthermore, the increasing application of injection pen in the treatment of various chronic diseases, lifestyle diseases and infertility problems enhance the market growth. Additionally, in November 2017, Merck announced the approval of its new GONAL-f RFF Redi-ject (follitropin alfa injection) prefilled pen by the U.S. FDA.

However, certain issues such as reimbursement issues in the developing nations and presence of alternative drug delivery devices can hamper the growth of the market.

Regional Analysis

The Americas is likely to dominate the global injection pen market owing to the increasing prevalence of cancer and diabetes in the population during the forecast period. In addition, well-established healthcare sector, favorable reimbursement scenario, and growing number of regulatory approvals further drive the growth of the market. According to the WHO, in 2016, 9.6% of total America population were suffering from diabetes. Europe is likely to hold the second position in the global injection pen market. The market growth is attributed to the availability of funds for research, increasing prevalence and government support for research and development. The Asia Pacific is the fastest growing market owing to the huge patient pool with chronic diseases and increasing healthcare expenditure. For instance, according to the WHO (2016), in China, 10% of adults were diagnosed with diabetes. It also stated that type 2 diabetes was found to be the most prevalent type of diabetes in China. The Middle East and Africa injection pen market are expected to grow slowly during the forecast period. Moreover, in this region, Middle East accounts for largest share owing to the increasing presence of prominent market players in the recent years.

Segmentation

The global injection pen market is segmented on the basis of the type, product, therapy, distribution channel, and end users. On the basis of the type, the market is classified into disposable injection pens and reusable injection pens. The global injection pen market on the basis of product is segmented into insulin pens and pen needles. On the basis of the therapy, the market is segmented as diabetes, growth hormone therapy, fertility, osteoporosis, multiple sclerosis, cardiovascular diseases, rheumatoid arthritis, obesity, Crohn’s disease, cancer, and others. Diabetes is further segmented into insulin and GLP-1.On the basis of distribution channel is segmented into hospital pharmacies, retail pharmacies, online medical stores, and diabetes clinics. On the basis of end users, the global injection pen market is segmented into home care and hospitals & clinics.

Global Injection Pen Key Players

Some the prominent players in the global injection pen market are  Novo Nordisk (Denmark), Eli Lilly (U.S.), Sanofi (France), Merck (U.S.), Ypsomed (Switzerland), AstraZeneca (U.K.), F.Hoffman-La Roche (Switzerland), Becton Dickinson and Company (US), Owen Mumford (U.K.), Novartis (Switzerland), Pfizer (U.S.), Haselmeier (Switzerland), Jiangsu Delfu medical device Co. Ltd (China), and Biocon Ltd (India).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/injection-pen-market-6146 

Botulism Illness Market 2019 Market Challenge, Driver, Trends & Forecast to 2023

 

Global Botulism Illness Market - Overview

The global botulism illness market is expecting a steady growth in coming future. Increasing prevalence of diseases, government support for the research and development and availability of the effective treatment for the botulism illness has driven the growth of the market.

Botulism illness is one of the rare and fatal paratactic disorder caused by neurotoxins produced by a bacteria Clostridium botulinum. Weakness, feeling tired, trouble in speaking and fever are some of the major symptoms of the disease. Botulism can be spread several different ways and is major caused due to food, water and neighbouring environment. According to the Centers for Disease Control and Prevention, in US every year, approximately 150 cases, are reported of which 15% are food borne, 65% are infant borne and remaining is caused due to wounds. Continuous increasing awareness and increasing health hygiene of the people helped to minimizing botulism.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/822  

Botulism is generally treated with antitoxin and supportive care. Supportive care for botulism includes monitoring of respiratory function. Antitoxin is required in case of both foodborne and wound botulism. Wounds should be treated, usually surgically, to remove the source of the toxin-producing bacteria followed by administration of appropriate antibiotics. Mechanical ventilators are needed when there is a breathing problem while rehabilitation therapies are needed in case of speaking or swallowing problem.

The global botulism illness market is expected to grow at a CAGR of 5.9% during the forecast period.

Global Botulism Illness Market - Regional Analysis

MerckMillipore, Sigma Aldrich, Fisher Scientific, Otsuka Chemical Co Ltd, Loba Chemie, Lenntech, Arkema SA,Bann Química, Chemtura Corporation, Behn Meyer Solutia Incorporated, Emerald Performance Materials, Lanxess AG, Eastman Chemicals Co and others are some of the prominent players at the forefront of competition in the global botulism illness market and are profiled in MRFR Analysis. 

Depending on geographic region, globally North America is the largest market for botulism illness. In North America, the US is one of the major markets for the treatment of botulism illness. The Centers for Disease Control and Prevention in the US has been looking forward to the proper treatment and care. Rising awareness and proper diagnose has meet the expectation of the North America, particularly in the U.S. region.

Europe is the second-largest market for botulism illness. European medical and healthcare associations along with WHO has implemented the proper treatment for botulism illness. Well-developed healthcare sector, increasing healthcare expenditure and increasing awareness among the people are the major factors for the growth of the market in America.

Asia pacific region is expected to be fastest growing region in botulism illness market. Presence of number of developing economies in this region is the major factor for the growth of the market. In some region of Asia Pacific people are not enough aware about the hygiene or not pay attention toward health hygiene. Increasing population and rapid development in the economies are also contributed in the growth of the market in Asia Pacific region. India and China are the major contributors for the market. Presence of huge population pool and rapidly developing healthcare sector with increasing healthcare expenditure has boosted the growth of this market in India and China.

Middle East & Africa accounts the least share for the market. Countries like UAE and Qatar are major contributors for the market in this area. Increasing awareness among the people are also contributed in the growth of the market.  However, high cost of R&D and long approval time for the drug are some of the hurdles expected to hinder the growth of botulism illness market.

Global Botulism Illness Market - Company Analysis

Global botulism illness market is a dominated by major players. Though there are many small companies present in the market but the huge share is acquired by major companies. Major players are trying to focus on acquisition and strategic alliances with local companies to minimize the competition.

Pfizer Inc. is one of the world's largest pharmaceutical companies headquartered in New York. It that develops and produces medicines and vaccines for a wide range of medical disciplines. Ultravac and Longrange are botulinum vaccine widely used in the treatment of the botulism.

Industry Updates

Sept, 2017 XOMA Corporation entered into a licensing agreement with Nanotherapeutics, Inc. received a milestone payment for the clinical advancements of an anti-botulism product licensed with Nanotherapeutics. With this approval, company will be able to sell the product globally.  

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/global-botulism-illness-market-822 

Atrial Fibrillation Market 2019 Market Challenge, Driver, Trends & Forecast to 2023

 Market Highlights

The global atrial fibrillation market is estimated to account for USD 11123.8 million and registering a CAGR of ~ 11.2 %. Atrial fibrillation is a disorder of the pace or the rhythm of the heart. It is caused by unsystematic electrical activity in the atria of the heart, which causes rapid stimulus of the ventricles, leading to an irregular heartbeat. Numerous factors such as advancements in minimally invasive surgeries to treat atrial fibrillation, appropriate and timely intervention of the healthcare delivery systems, and increased incidence rates of the risk factors are expected to drive the growth of the market during the forecast period. According to the Centers for Disease Control and Prevention, Atrial fibrillation (AFib) costs the United States about USD 6 billion annually. Medical costs for people who have AFib are about USD 8,705 higher per year than for people who do not have AFib. Therefore, the ability of the specialist to suspect and diagnose the condition is very important. The lack of technical knowledge and misdiagnosis and mismanagement of the condition may hamper the market growth.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6520 

The global atrial fibrillation market is currently dominated by many market players. The key players in the market are engaged in new product launches and strategic collaborations to strengthen its market position. For instance, in January 2017, Abbott completed the acquisition of St. Jude Medical, Inc. St. Jude Medical's strong positions in fast-growing areas such as atrial fibrillation, heart failure, structural heart and chronic pain balance Abbott's leading positions in coronary interventions and mitral valve disease and will further create a strong and diverse product portfolio.

Regional Analysis

The market in the Americas is expected to dominate the global atrial fibrillation market during the forecast period due to the escalation in the adoption of advanced technologies and procedures for the treatment of atrial fibrillation, and well-developed healthcare infrastructure. According to the Centers for Disease Control and Prevention in 2017, an estimated 2.7–6.1 million people in the United States have atrial fibrillation (AFib). The European market is expected to be the second-largest due to government funding and support of the healthcare sector. Also, many companies are setting up their research and development centers in this region, which will boost the market growth in this region. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the assessment period owing to growing disposable income, and huge population susceptible to cardiovascular diseases. The market in the Middle East & Africa is likely to account for the smallest share of the global atrial fibrillation market.

Segmentation

The global atrial fibrillation market has been segmented into type, treatment, and end-user.

The market, on the basis of type, has been segmented into paroxysmal atrial fibrillation, persistent atrial fibrillation, and permanent atrial fibrillation.

The permanent type of atrial fibrillation is anticipated to hold the largest share as it is the most common type of AFib with a high occurrence rate. The persistent atrial fibrillation segment is estimated to be the fastest growing owing to increased recurrence rates in patients.

The market, on the basis of treatment, has been segmented into medications, non-surgical procedures, and surgical procedures.

The market, based on medications, has been segmented blood thinners, rate controllers, and rhythm controllers.

The market, based on non-surgical procedures, has been segmented into electrical cardioversion and catheter ablation.

The market, based on surgical procedures, has been segmented into pacemaker implantation and open-heart maze procedure.

Key Players

Some of the key players in the global atrial fibrillation market are Medtronic Plc, Johnson & Johnson Services, Inc., Abbott, Boston Scientific Corporation, MicroPort Scientific Corporation, Biotronik SE & Co. KG, Koninklijke Philips N.V., AtriCure, Inc., CardioFocus, Osypka AG, Siemens AG, Biosense Webster, Inc., Sichuan Jinjiang Electronic Science and Technology Co., Ltd., CathRx Ltd., and Vanguard AG.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/atrial-fibrillation-systems-market-6520 

Stem Cell Assay Market 2019 Global– Key Players, Size, Trends, Growth- Analysis To 2023

 

Market Insights:

Stem Cells have been acknowledged for their promising potential toward the development of various cutting-edge treatments for a number of diseases. As such, stem cell assays have a rapidly growing market. Stem cell assays are essentially the techniques used for analyzing living cells by various parameters which ultimately help determine the biochemical and cellular functioning of cells. This has immense promise in drug development activities. Market Research Future's study of the market in its latest report has found that the globalstem cell assay market is on track to register a highly optimistic outlook at a CAGR of 19.80% during the review period from 2017 to 2023.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5656 

Stem cell assays are a promising part of the biotechnology field, which is growing at a rapid pace. The prevalence of chronic and several lifestyle diseases has compelled the growth of drug development activities in an effort to develop effective treatments. Diseases such as cancer and diabetes are soaring at high rates and the demand for better, efficient and more affordable treatments are driving the market toward growth. Healthcare expenditure across the globe is increasing, and advancement in biotechnology and other medical technologies is highly encouraging of market growth. Government support toward drug development for chronic diseases has increased stem cell assay research.

The market is held back by stringent government policies associated with approval of drugs as well as the high procedural cost of stem cell assays. Moreover, there is a lack of awareness regarding stem cell assays, and as a result, there is a dearth of skilled professionals which restrains market growth. However, growing healthcare activities and the increasing demand for treatment is likely to bring stem cell assays to the forefront and opportunities in the market are plentiful.

Market Segmentation:
Market structure is determined by its various significant sections which, in the report have been segmented on the basis of product, technology, assay, application, end-user, and region. Products in the market include flow cytometer, cell imaging systems, automated cell counter, kits, and others. The kits segment has been sub-segmented and includes umbilical cord stem cells, induced pluripotent stem cell kits, mesenchymal stem cell kits, and others.

The technology used in stem cell assays include microfluidics-based cell trap technologies, microfabricated assisted technology, and others

Assays in the market include cell identification assays, cell viability & toxicity assays, cell proliferation assays, cell apoptosis assays, and others.

Applications of stem cell assays can be found in orthopedic & musculoskeletal spine, dermatology, cardiovascular, central nervous system, and others.

End-users of stem cell assays include research organizations, academic institutes, biotechnology industries, academic institutes, and others.

Regional Analysis:
The Americas have captured the dominant share of the global market. The presence of North America in the region has had a significant impact on the regions market share possession. The rapid adoption of advanced medical technologies and the presence of a large patient population for various chronic diseases drive the Americas' market. Moreover, the regions healthcare expenditure is rising, and there are several leading players present in the North American sub-market.

Meanwhile, growing at the fastest pace is the Asia Pacific regional market. Gradually increasing awareness regarding advanced medical biotechnology is strongly impacting growth in the region. Several emerging economies in the region have a rapidly growing biotechnology sector which fuelling market growth. Findings by the Indian Brand Equity Foundation suggest that the Indian subcontinent has 2% of the global biotechnology share. Several opportunities in the region are expected to lead to market proliferation.

Key Players:
Prominent players included in MRFR’s report are Cell Biolabs, Inc., Thermo Fisher Scientific, Hemogenix, Merck KGaA, Promega Corporation, GE Healthcare, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cellular Dynamics International Inc., STEMCELL Technologies Inc., and others

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/stem-cell-assay-market-5656

The Paraneoplastic Syndrome Market Staggering Double Digit Cagr Driven By Advanced & Cost Effective Technologies Forecasts Till 2023

 Market Research Future adds the “Paraneoplastic Syndrome Market Research Report - Forecast to 2023” report to their unique collection.

Paraneoplastic Syndrome Market Highlights:

Schizophrenia is a chronic and severe mental disorder that affects the thinking, feeling, and behavior of the A paraneoplastic syndrome is a set of signs and symptoms which develops from tumor or cancer. This syndrome can be mostly seen in middle-aged to older patients and are often seen in patients suffering from breast cancer, lung cancer, and lymphatic or ovarian cancer. Sometimes, patients with paraneoplastic syndrome do not show symptoms even after the diagnosis, but there exists a rare condition where patients show symptoms of the paraneoplastic syndrome even before diagnostic tests are carried out.

The global paraneoplastic syndrome market is dominated by many market players. The key players in the market are engaged in new launches and strategic collaborations to hold their market position.

Also Read : https://www.medgadget.com/2019/01/paraneoplastic-syndrome-market-outlook-2023-in-depth-research-on-diagnostics-treatment-and-management-development-prospective-report-2019.html 

Paraneoplastic Syndrome Market: The increasing prevalence of cancer and tumor-related problems is projected to boost the market growth during the forecast period from 2018 to 2023

Factors such as the increasing prevalence of cancer, awareness regarding breast cancer, and an unhealthy lifestyle drive the growth of the global paraneoplastic syndrome market. Moreover, rising investments in research and development activities and increasing healthcare expenditure are few more factors driving the global paraneoplastic syndrome market.

On the other hand lack of awareness regarding cancer and stringent regulations may hamper the growth of the market.

Comprehensive Regional Analysis

The Americas is anticipated to dominate the global paraneoplastic syndrome market. The market growth in this region is attributed to the increasing geriatric population with paraneoplastic syndrome disorder, investment in research and development, and technological advancements.

Europe is expected to be the second largest market in the globe owing to the increasing number of geriatric population, increasing awareness regarding breast cancer, the presence of disposable income, and increasing consumption of tobacco in this region.

Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of paraneoplastic syndrome and cancer-related problems in developing countries, increasing disposable income, and growing healthcare expenditure.

The Middle East and Africa is expected to account for the lowest market share in the global paraneoplastic syndrome market due to low development, lack of technical knowledge, and poor medical facilities in developing economies in this region.

Intended Audience

• Hospitals and clinics
• Laboratories and associations
• Healthcare providers
• Research institutes and academic centers
• Government associations
• Market research and consulting

Competitive Analysis by Major Key Players

Some of the key players in the global paraneoplastic syndrome market are Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation.

Industry Segmentation

The global paraneoplastic syndrome market has been segmented into types, diagnosis, treatment, and end users. Based on types, the market is segmented into the cutaneous paraneoplastic syndrome, gastro-intestinal paraneoplastic syndrome, endocrine paraneoplastic syndrome, hematologic paraneoplastic syndrome, renal paraneoplastic syndrome, rheumatologic paraneoplastic syndromes, and neurologic paraneoplastic syndrome.

The market, by treatment, has been segmented into medication and therapies. Medication is further sub-segmented into corticosteroids, immunosuppressants, anti-seizure medications, plasmapheresis, and intravenous immunoglobulin (IVIg). On the basis of therapies, the market is further sub-segmented into physical therapy and speech therapy.

The market on the basis of diagnosis has been segmented into blood test, spinal tap (lumbar puncture), and imaging tests. Imaging tests are further sub-segmented into computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and PET plus CT.

Based on end-user, the market is segmented into hospitals and clinics, diagnostic centers, and ambulatory care centers.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/paraneoplastic-syndrome-market-6524   

About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar, Pune

+1 646 845 9312

Email: sales@marketresearchfuture.com

Electrical Hospital Beds Market Worldwide Key Players Forecasts By Revenue, Growth Rate Till 2023

 Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Electrical Hospital Beds Market Research Report - Forecast to 2023” Gives industry size, top players and worldwide demand

Global Electrical Hospital Beds Market Research Report: by Type (Semi-automatic, Automatic), by Treatment (Critical Care, Acute Care, Long Term Care), by Application (General Purpose, Psychiatric), by End-user (Hospitals & Clinics, Reproductive Care Centers, Dentistry, Home Care), and Region – Forecast to 2023

The Global Electrical Hospital Beds Market is likely to attain a valuation of USD 2,595.4 Mn at a CAGR of 7.25% by the end of the forecast period of 2018-2023, asserts Market Research Future (MRFR) in an in-depth study. Electrical hospital beds are of paramount importance to patients with reduced mobility. Patients with acute disease conditions such as paralysis, spinal injuries, and others have witnessed a surge in number in recent years, and electrical hospital beds are increasingly gaining traction among such patients. Electrical hospital beds can be operated with minimal assistance and are of great help to ailing patients. Medical emergency units generate a high demand for electrical hospital beds since medical emergency rooms experience an influx of patients with severe medical ailments.

Also Read : https://www.medgadget.com/2019/04/electrical-hospital-beds-market-projected-to-grow-radiantly-at-18-cagr-by-2023-medline-industries-inc-getinge-ab-arjohuntleigh-stryker-corporation-etc.html 

A growing number of accidents, wars, and natural calamities have prompted hospitals to delegate more space for emergency rooms which has further induced demand for electrical hospital beds. Furthermore, the government in multiple countries are revamping their healthcare sector which is providing a boost to the growth of the electrical hospital beds market. Technological advancements which result in improvising of electrical hospital beds and consequently leads to the increased sale of electrical hospital beds. On the flipside, the growth of electrical hospital beds market might be deterred by high costs and high maintenance costs.

Key Players :

Market Research Future (MRFR) recognizes the following companies as the key players in Electrical Hospital Beds Market: There are plenty of large and small market players which operate in this market all over the globe.

The eminent players in the global electrical hospital beds market include Span America Medical System, Inc. (U.S.), Paramount Bed Holding Co., Ltd. (Japan), Famed Zywiec Sp.zo.o. (Poland), Hill Room Holding (U.S.), Stryker Corporation (U.S.), Invacare Corporation (U.S.), Amico Group of Companies (Canada), Medline Industries, Inc. (U.S.), Getinge AB (Sweden), ArjoHuntleigh (Sweden), Malvestio Spa (Italy), Midmark Corporation (U.S.), Merivaara Corporation (Finland), Gendron, Inc. (U.S.), and Linet spol.s.r.o. (Czech Republic).

Segments :

The global electrical hospitals beds market has been segmented based on type, type of treatment, application, and end user.

By type, the global electrical hospital beds market has been segmented into semi-automatic bed and fully automatic bed. The fully automatic beds segment currently stands at USD 1,029 Mn and is likely to scale up to USD 1,570.9 Mn by 2023 and capture the highest CAGR of 8.83% over the forecast period. Semi-automatic beds segment is likely to strike a CAGR of 5.07% over the forecast period.

By type of treatment, the global electrical hospital beds market includes critical care, acute care, and long-term care. The critical care segment is the largest as well as the fastest growing segment and is expected to expand at a CAGR of 8.03% over the forecast period to scale valuation of USD 1,020.6 Mn. The acute care segment is expected to be the second largest segment and is expected to attain USD 865.4 Mn by 2023.

By application, the global electrical hospital beds market has been segmented into general purpose, intensive care, delivery/birthing, bariatric, pediatric, pressure relief, psychiatric care, and others. The general purpose segment is leading the market and is expected to reach a market valuation of USD 836.4 Mn by 2023 with a CAGR of 7.29% over the forecast period. The intensive care segment is expected to be the fastest growing segment and capture a CAGR of 7.82% over the forecast period.

By end-user, the global electrical hospital beds market has been segmented into hospital & clinics, reproductive care centers, dentistry, home, & others. Hospitals & clinics segment is dominating the market and is expected to expand at a CAGR of 7.25% over the forecast period.  However, homecare segment is expected to be the fastest growing segment and register a CAGR of 8.81% over the forecast period.

Regional Analysis :

By region, the global electrical hospital beds market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).

Europe is the largest market for electrical hospital beds and accounted for 34% share of the global market in 2017. Presence of sophisticated healthcare infrastructure and greater emphasis on patient health and comfort in the region drives the market. The U.K., France, and Germany are the key contributors to the Europe market which can scale valuation of USD 906.4 Mn by the end of 2023.

The Americas is the second largest market for electrical hospital beds driven by high healthcare spending in strong economies such as the US and Canada.

APAC market is anticipated to exhibit rapid growth over the forecast period. High investment on the development of healthcare infrastructure, the growth of medical tourism and availability of a massive patient pool creates favorable growth opportunities for the market growth. The APAC market is estimated to strike a CAGR of 8.47% over the forecast period.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/electrical-hospital-beds-market-6552 

Worldwide Liquid Handling System Market Witness A Remarkable Growth Projected By 2023

 This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Liquid Handling System Market over the forecast period.

Global Liquid Handling System Research Report: By Type (Manual, Automated, Electronic), by Product (Consumables, Pipettes, Others), by Application (Drug Discovery, Others), by End User (Pharmaceutical & Biotechnology Companies, Others)—Forecast till 2023

Also Read : https://www.medgadget.com/2019/04/liquid-handling-system-market-2019-growth-factors-details-recent-industry-status-competitors-analysis-by-region-and-forecast-2023.html 

Key Players for Global Liquid Handling System Market

Market Research Future (MRFR) recognizes the following companies as the key players in Liquid Handling System Market: There are plenty of large and small market players which operate in this market all over the globe.

Some of the prominent players in the Global Liquid Handling System Market are Agilent Technologies, Danaher Corporation, Thermo Fisher Scientific, Inc., Eppendorf AG, Tecan Group Ltd., Bio-Rad Laboratories, Sartorius AG, Mettler-Toledo International Inc., PerkinElmer, Inc., Corning Incorporated, and Hamilton Company.

Liquid Handling System Market – Overview

The Global Liquid Handling System Market is anticipated to hold a market value of USD 2.95 billion in the year 2017 and is expected to grow at a CAGR of 8.7% during the forecast period. Liquid handling system is generally used in the pharmaceutical, life science, or biochemical laboratories. The liquid handling system can perform simple, monotonous routine tasks as well as complex pipetting task efficiently.

The growing investments in drug development, increasing demand for high-output screening, rising expenditure on research & development (R&D), and increasing adoption of automation in clinical settings are anticipated to propel the market growth during the assessment period. According to the data by The World Bank, the research and development expenditure (as % of Gross Domestic Product) was 1.70% in the United Kingdom in 2015. On the other hand, the high cost associated with the liquid handling systems and complex operability of the latest liquid handling systems may hamper the growth of the market over the forecast period.

Currently, a large number of companies are engaged in developing liquid handling systems. For instance, Microlab VANTAGE, Microlab STAR, and Microlab NIMBUS are some liquid handling systems developed by Hamilton Company.

Segments for Global Liquid Handling System Market

The Global Liquid Handling System Market has been segmented into type, product, application, and end user.

The Global Liquid Handling System Market, on the basis of type, has been segmented into manual, automated, and electronic liquid handling system. The electronic liquid handling system segment held the largest market share in 2017 due to the high accuracy and reproducibility offered by the electronic liquid handling system.

The Global Liquid Handling System Market, on the basis of product, has been segmented into pipettes, consumables, microplate reagent dispensers, liquid handling workstations, burettes, software, and others. The pipette segment has been segmented into manual pipettes, electronic pipettes, and semi-automated pipettes. The consumables segment has been segmented into disposable tips, tubes and plates, reagent containers, and others.

The global market, on the basis of application, has been segmented into drug discovery, genomics, clinical diagnostics, proteomics, and others. The drug discovery segment has been segmented into ADME screening, high-throughput screening (HTS), compound weighing and dissolution, and others. The genomics segment has been segmented into genotyping, next-generation sequencing (NGS), polymerase chain reaction (PCR), DNA/RNA purification, and others. The clinical diagnostics segment has been segmented into sample preparation, ELISA, and others.

The global market, by end user, has been segmented into pharmaceutical & biotechnology companies, contract research organization (CRO), and others.

Regional Analysis for Global Liquid Handling System Market

Geographically, the Americas is expected to dominate the global market owing to the presence of well-established healthcare sector, the high adoption rate of advanced technologies, and rising healthcare expenditures. Europe is anticipated to be the second largest market in the global liquid handling system market owing to the increasing R&D activities and continuously growing biopharmaceutical sector. Asia-Pacific region is anticipated to be the fastest growing region due to the improving scenario of life sciences-related research, increasing development in the healthcare sector, and rising government investments in the biotechnology and pharmaceutical sector. Furthermore, the Middle East & Africa has the lowest share of the global liquid handling system market.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/liquid-handling-system-market-6588